prIME Clinical Updates From the 2015 Annual Hematology Meeting in Orlando - priME Oncology
prIME Clinical Update
prIME Clinical Update

prIME Clinical Updates From the 2015 Annual Hematology Meeting in Orlando

Not a member of My prIME? Join now for instant access.

Release Date

Release Date

Dec 8, 2015

Expiration Date

Dec 8, 2016

IME

IME

Downloadable Slides

Downloadable Slides

View CME-certified expert discussions focusing on recent updates in chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndromes, multiple myeloma, and non-Hodgkin lymphoma released at the 2015 Annual Hematology Meeting in Orlando.

CME

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

accme

prIME Oncology designates this enduring activity for a maximum of 2.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Meletios Dimopoulos, MDUniversity of Athens
    Athens, Greece
  • Janice Galleshaw, MDprIME Oncology
    Atlanta, Georgia
  • Elias Jabbour, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Thomas Kipps, MD, PhDUC San Diego Moores Cancer Center
    La Jolla, California
  • Shaji Kumar, MDMayo Clinic
    Rochester, Minnesota, United States
  • John P. Leonard, MDWeill Cornell Medical College
    New York, New York, United States
  • Sagar Lonial, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States
  • Philippe Moreau, MDUniversity of Nantes
    Nantes, France
  • S. Vincent Rajkumar, MDMayo Clinic
    Rochester, Minnesota, United States
  • Jesús San Miguel, MD, PhDUniversidad de Navarra
    Pamplona, Spain
  • Mikkael Sekeres, MD, MSCleveland Clinic
    Cleveland, Ohio, United States
  • Julie Vose, MD, MBAUniversity of Nebraska Medical Center
    Omaha, Nebraska, United States
  • Elisabetta Abruzzese, MDSan Eugenio Hospital
    Rome, Italy
  • Sonia M. Abuzakhm, MDColumbus Oncology & Hematology Associates
    Columbus, Ohio, United States
  • Frédéric Amant, MD, PhDCatholic University
    Leuven, Belgium

Topics

Topics

Target Audience

This activity is intended for practicing hematologists, oncologists, and other healthcare professionals involved in the treatment of patients with cancer in the United States.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Select the most appropriate therapy for patients with hematologic malignancies based on expert guidelines and recent clinical data
  • Identify critical aspects of response monitoring, including aspects like depth and timing of response
  • Identify important ongoing clinical trials for the hematologic malignancies and disorders

Support

This educational activity is supported by grants from Takeda Oncology; Celgene Corporation; Genentech; Pharmacyclics LLC, an AbbVie Company; and Bristol-Myers Squibb.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

accme

prIME Oncology designates this enduring activity for a maximum of 2.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Chronic Lymphocytic Leukemia: 0.5
  • Chronic Myeloid Leukemia: 0.25
  • Myelodysplastic Syndromes: 0.5
  • Multiple Myeloma—Frontline: 0.25
  • Multiple Myeloma—Relapsed/Refractory: 0.5
  • Multiple Myeloma—Immunotherapy: 0.25
  • Non-Hodgkin Lymphoma: 0.5

Provider

This activity is provided by prIME Oncology.

prime

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttests are available on the video player pages.

In order to claim credit for these activities, a score of 75% or higher is required on each test.

Disclosure of Relevant Financial Relationships

Dr Dimopoulos has disclosed that he has received consulting fees from Celgene, Janssen, Onyx, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Galleshaw has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Jabbour disclosed that he has received consulting fees from Ariad, Bristol-Myers Squibb, Novartis, Pfizer, and Teva. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kipps has disclosed that he has received consulting fees from AbbVie, Genentech/Roche, Gilead, and Pharmacyclics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kumar disclosed that he has received consulting fees from Skyline. He has also performed contracted research for Abbvie, Celgene, Janssen, Novartis Oncology, Onyx, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Leonard has disclosed that he has received consulting fees from ADC Therapeutics, Biotest, Boehringer Ingelheim, Celgene, Eisai, Genentech, Gilead, MedImmune, Mirati, Novartis, Pfizer, ProNAi, Seattle Genetics, Spectrum Pharmaceuticals, Teva, and Vertex. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lonial has disclosed that he has received consulting fees from Bristol-Myers Squibb, Celgene Corporation, Millennium, Novartis Oncology, and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Moreau has disclosed that he has received consulting fees from Celgene, Janssen, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Rajkumar has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr San Miguel has disclosed that he has received consulting fees from Bristol-Myers Squibb, Celgene, Janssen, Millennium, MSD, Novartis, and Onyx. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Sekeres has disclosed that he has received consulting fees from Celgene and Tetralogic. He has also received fees for data safety boards from Amgen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vose has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.